RESUMEN
Cyclospora cayetanensis infections are prevalent worldwide, and the parasite has become a major public health and food safety concern. Although important efforts have been dedicated to advance toward preventing and reducing incidences of cyclosporiasis, there are still several knowledge gaps that hamper the implementation of effective measures to prevent the contamination of produce and water with Cyclospora oocysts. Some of these data gaps can be attributed to the fact that access to oocysts is a limiting factor in C. cayetanensis research. There are no animal models or in vivo or in vitro culture systems to propagate the oocysts needed to facilitate C. cayetanensis research. Thus, researchers must rely upon limited supplies of oocysts obtained from naturally infected human patients considerably restricting what can be learnt about this parasite. Despite the limited supply of C. cayetanensis oocysts, several important advances have happened in the past 3 years. Great progress has been made in the Cyclospora field in the areas of molecular characterization of strains and species, generation of genomes, and development of novel detection methods. This comprehensive perspective summarizes research published from 2020 to 2023 and evaluates what we have learnt and identifies those aspects in which further research is needed.
RESUMEN
Cyclospora cayetanensis infection has emerged as a significant public health concern worldwide. Developed countries are generally considered non-endemic for infection. However, sporadic cases and non-travel-related outbreaks of C. cayetanensis infections associated with domestically grown produce are becoming more common in developed countries. Cyclospora cayetanensis has been detected in fresh produce, surface water, wastewater, irrigation water, and soil in these countries, suggesting that the parasite may be more common in areas with advanced sanitation than previously thought and illustrating the potential risk for exposure and indigenous/autochthonous infections. The evidence suggests the possibility of foci of endemicity in developed countries, particularly in communities where sanitary conditions are compromised, and raises transmission issues that require further research to better define the risks for infection, how widespread C. cayetanensis may be in these areas, and to guide interventions against this infection. The main purpose of the present opinion was to evaluate the presence of cyclosporiasis in developed countries, which is a very important and ongoing issue in food safety.
RESUMEN
BACKGROUND: Transmission dynamics of Cyclospora cayetanensis in endemic areas and the factors associated with soil contamination remain unclear. The effects of environmental factors on Cyclospora have been insufficiently studied, particularly in South America, thus a Venezuelan community was studied to profile risk factors for infection. METHODS: A cross-sectional stool survey of 732 individuals was conducted. For Cyclospora screening, an acid-fast-stained smear of formalin-ethyl acetate concentrate and ultraviolet (UV) epifluorescence examination of a wet mount were used. Water (n=14), soil (n=50) and produce (n=77) samples were collected, processed and examined by UV epifluorescence. Data were analysed using multivariate logistic regression. RESULTS: Cyclospora infections were identified in 73 (9.9%) subjects. Variables associated with the infection were age ≤10 y (odds ratio [OR] 14), hut living (OR 5), well water use (OR 18.5), drinking untreated water (OR 7.6), toilet absence (OR 8), having contact with faeces-contaminated soil (OR 4) and poultry exposure (OR 3). Infections (63%) were clustered in 25 huts. Oocysts were identified in 28.6%, 18% and 3.9% of the water, soil and produce samples, respectively. CONCLUSIONS: There was an explicit association of Cyclospora infection with extreme poverty and soil transmission reflecting the household socio-economic correlate of cyclosporiasis in this community.
Asunto(s)
Cyclospora , Ciclosporiasis , Humanos , Ciclosporiasis/epidemiología , Ciclosporiasis/diagnóstico , Suelo , Estudios Transversales , Pobreza , AguaAsunto(s)
Vacunas contra la COVID-19/inmunología , COVID-19/inmunología , Coinfección/inmunología , Helmintiasis/inmunología , Helmintos/inmunología , Vacunación Masiva , SARS-CoV-2/inmunología , Clima Tropical , Animales , COVID-19/complicaciones , COVID-19/epidemiología , Preescolar , Helmintiasis/complicaciones , Helmintiasis/epidemiología , Humanos , Inmunidad Innata , Inflamación , Células Th2/inmunologíaRESUMEN
Melatonin, a hormone secreted by the pineal gland, works directly and indirectly as a free radical scavenger. Its other physiological or pharmacological activities could be dependent or independent of receptors located in different cells, organs, and tissues. In addition to its role in promoting sleep and circadian rhythms regulation, it has important immunomodulatory, antioxidant, and neuroprotective effects suggesting that this indole must be considered as a therapeutic alternative against infections. The aim of this review is to describe the effects of melatonin on oxidative stress and the resistance to bacterial (Klebsiella pneumoniae, Helicobacter pylori, Mycobacterium tuberculosis, and Clostridium perfringens), viral (Venezuelan equine encephalomyelitis virus and respiratory syncytial virus), and parasitic (Plasmodium spp., Entamoeba histolytica, Trypanosoma cruzi, Toxoplasma gondii, and Opisthorchis viverrini) infections.
Asunto(s)
Infecciones Bacterianas/inmunología , Resistencia a la Enfermedad/efectos de los fármacos , Factores Inmunológicos/metabolismo , Melatonina/metabolismo , Estrés Oxidativo/efectos de los fármacos , Enfermedades Parasitarias/inmunología , Virosis/inmunología , Antioxidantes/metabolismo , Infecciones Bacterianas/prevención & control , Humanos , Enfermedades Parasitarias/prevención & control , Virosis/prevención & controlRESUMEN
Sexually transmitted infections (STIs) are often discussed in the context of syphilis, gonorrhea, herpes, chlamydiasis and AIDS. However, since the past 30 years of the last century, epidemiology and natural history studies have led to improved understanding of giardiasis as a STI, as a result of oral-anal sexual contact. Studies suggest that Giardia is an increasingly recognized infection that may be underdiagnosed under the STI context. Health care providers should maintain a high index of suspicion for Giardia, obtain suitable diagnostic tests to identify and screen those at high risk for this infection, institute appropriate therapy, counsel patients regarding treatment compliance, follow-up, encourage partner notification and teach strategies for preventing the transmission of this disease, including the discussion of the risk of enteric infections after oral-anal sexual contact. We summarize some data concerning the research and clinical literature on Giardia infection as a STI and identify the specific recommendations for control of giardiasis as STI that available evidence indicates can reduce its transmission.
Asunto(s)
Control de Enfermedades Transmisibles/métodos , Transmisión de Enfermedad Infecciosa/prevención & control , Giardiasis/epidemiología , Giardiasis/transmisión , Enfermedades de Transmisión Sexual/epidemiología , Enfermedades de Transmisión Sexual/prevención & control , Giardiasis/diagnóstico , Giardiasis/prevención & control , Humanos , Enfermedades de Transmisión Sexual/diagnóstico , Enfermedades de Transmisión Sexual/tratamiento farmacológicoRESUMEN
The description of Entamoeba dispar, and the recovery of Entamoeba moshkovskii from humans had a major impact in the epidemiology and clinical management of amebiasis. Infections range from asymptomatic colonization to hemorrhagic colitis and extra-intestinal diseases. Only a minority of amebiasis patients progress to the development of disease. Recent studies suggest that susceptibility to infection, and its outcome is influenced by the host, parasite genotype, and environment. The identification of Entamoeba histolytica is based on the detection of specific antigens by ELISA and DNA in stool and other clinical samples. Several diagnostic tests have been developed, including polymerase chain reaction, the technique of choice, for the detection and differentiation of E. histolytica, E. dispar, and E. moshkovskii. Combination of serologic tests with detection of the parasite DNA by PCR or antigen by ELISA offers the best approach to diagnosis. However, these techniques are impractical for clinical laboratories of developing countries. Clinicians must follow the guidelines of the World Health Organization to avoid unnecessary treatments. This review describes and discusses recent advances in amebiasis with emphasis in the clinical aspects and management of infection.
Asunto(s)
Amebiasis , Amebiasis/diagnóstico , Amebiasis/tratamiento farmacológico , Amebiasis/parasitología , ADN Protozoario/genética , Entamoeba histolytica/patogenicidad , Ensayo de Inmunoadsorción Enzimática , Heces/parasitología , Interacciones Huésped-Parásitos , Humanos , Reacción en Cadena de la PolimerasaRESUMEN
In today's world, parasitic disease agents are not restricted by geography or economy, and have become a significant global threat. The increasing globalization of the fresh produce market and greater international trade and travels, have contributed to the spread of these organisms in the industrialized world. Parasitic protozoa cause waterborne and foodborne outbreaks of diarrhea. The unprecedented flow of people introduces cultural and behavior patterns around the world; the increasing tendency to eat raw or undercooked meat and seafood, favors the dissemination of several parasitic pathogens. Climate changes are predicted to cause a global increase in soil-transmitted helminthiases. The multidisciplinary study of these agents, and the interaction among scientists, global health organizations and governments are imperative to reduce the burden of these diseases and improve the life of a large segment of the world population.
Asunto(s)
Salud Global , Parasitosis Intestinales/epidemiología , Animales , Comercio , Enfermedades Transmisibles Emergentes , Brotes de Enfermedades , Contaminación de Alimentos , Parasitología de Alimentos , Predicción , Calentamiento Global , Humanos , Comunicación Interdisciplinaria , Cooperación Internacional , Parasitosis Intestinales/prevención & control , Parasitosis Intestinales/transmisión , Justicia Social , Zoonosis/epidemiologíaRESUMEN
The description of Entamoeba dispar, and the recovery of Entamoeba moshkovskii from humans had a major impact in the epidemiology and clinical management of amebiasis. Infections range from asymptomatic colonization to hemorrhagic colitis and extra-intestinal diseases. Only a minority of amebiasis patients progress to the development of disease. Recent studies suggest that susceptibility to infection, and its outcome is influenced by the host, parasite genotype, and environment. The identification of Entamoeba histolytica is based on the detection of specific antigens by ELISA and DNA in stool and other clinical samples. Several diagnostic tests have been developed, including polymerase chain reaction, the technique of choice, for the detection and differentiation of E. histolytica, E. dispar, and E. moshkovskii. Combination of serologic tests with detection of the parasite DNA by PCR or antigen by ELISA offers the best approach to diagnosis. However, these techniques are impractical for clinical laboratories of developing countries. Clinicians must follow the guidelines of the World Health Organization to avoid unnecessary treatments. This review describes and discusses recent advances in amebiasis with emphasis in the clinical aspects and management of infection.
Asunto(s)
Humanos , Amebiasis , Amebiasis/diagnóstico , Amebiasis/tratamiento farmacológico , Amebiasis/parasitología , ADN Protozoario/genética , Entamoeba histolytica/patogenicidad , Ensayo de Inmunoadsorción Enzimática , Heces/parasitología , Interacciones Huésped-Parásitos , Reacción en Cadena de la PolimerasaAsunto(s)
Animales , Humanos , Salud Global , Parasitosis Intestinales/epidemiología , Comercio , Enfermedades Transmisibles Emergentes , Brotes de Enfermedades , Contaminación de Alimentos , Parasitología de Alimentos , Predicción , Calentamiento Global , Comunicación Interdisciplinaria , Cooperación Internacional , Parasitosis Intestinales/prevención & control , Parasitosis Intestinales/transmisión , Justicia Social , Zoonosis/epidemiologíaRESUMEN
The number of h papers with at least h citations (h-index) has been proposed to evaluate individual scientific research production. This new indicator of academic impact has raised a widespread interest and is growing in popularity. The advantage of this factor is that it combines an assessment of both quantity and quality of the h papers. However, it has limitations and it is not completely suitable to evaluate the research quality of professionals. To avoid these disadvantages, some indicators have been proposed. The authors emphasize the need for combining several indicators in the evaluation process.
Asunto(s)
Factor de Impacto de la Revista , Edición/estadística & datos numéricosRESUMEN
Although many drugs destroy Entamoeba histolytica within the colonic lumen, the number of tissue amebicides used to treat invasive amebiasis is still relatively limited. Metronidazole (MTZ), which is the drug of choice for invasive amebiasis, and other nitroimidazoles have greatly simplified the chemotherapy of this disease. However, eradication of E. histolytica infection after completion of MTZ therapy requires additional treatment with luminal amebicides, such as paramomycin. After decades of the introduction of MTZ and other nitroimidazoles in the therapy of amebiasis, there have been few innovations in treating amebic infections. Meanwhile, amebiasis remains among the leading causes of morbidity and mortality in the contemporary world. The toxic effects of MTZ and recent failures in the treatment of several intestinal protozoan parasites, has led to a search for other amebicidal drugs. A recent advance is the demonstration of the effect of nitazoxanide, which has broad spectrum of antiparasitic activity, against E. histolytica. This compound could be the key in the therapy of amebiasis by its action against both luminal and invasive parasite forms. However, the design of an effective vaccine against the infection is still being desirable. Work is underway to develop a vaccine and recent experimental studies are promising. The aim of this review is to examine and discuss the most important aspects of current antiamebic pharmacotherapy and the prospects for development of new drugs and a vaccine.
Asunto(s)
Amebiasis/tratamiento farmacológico , Amebicidas/uso terapéutico , Vacunas , Diseño de Fármacos , HumanosRESUMEN
Aunque existe una gran cantidad de fármacos amebicidas que actúan en la luz intestinal, las drogas de acción tisular usadas para tratar la amibiasis invasiva son aún relativamente limitadas. El advenimiento del metronidazol (MTZ), que es el fármaco de elección para la amibiasis invasiva, y otros nitroimidazoles en el tratamiento de la amibiasis, ha simplificado enormemente la quimioterapia de la infección. No obstante, la erradicación de ésta después de la administración del MTZ requiere terapia adicional con un amebicida de acción luminal como la paramomicina. Después de décadas desde la introducción de estas drogas en la terapia de la infección, se han hecho pocas innovaciones. Mientras tanto, esta parasitosis continúa siendo una causa importante de morbilidad y mortalidad en el mundo contemporáneo. Debido a los efectos tóxicos y los recientes fracasos en el tratamiento de algunos protozoos intestinales con el MTZ, es necesaria la búsqueda de nuevos compuestos amebicidas. Un avance reciente es la nitazoxanida que tiene una actividad de amplio espectro contra diversos agentes infecciosos y se ha demostrado recientemente su acción contra E. histolytica. Este fármaco podría ser clave como amebicida por su efectividad contra el parásito en la luz intestinal y en los tejidos. Sin embargo, el diseño de una vacuna protectora contra la infección sigue siendo deseable. Los estudios experimentales recientes en animales modelo son alentadores. El objetivo de esta revisión es examinar y discutir los aspectos más importantes de la farmacoterapia actual de la amibiasis, así como de los prospectos para el desarrollo de nuevas drogas y una vacuna protectora contra la infección.
Although many drugs destroy Entamoeba histolytica within the colonic lumen, the number of tissue amebicides used to treat invasive amebiasis is still relatively limited. Metronidazole (MTZ), which is the drug of choice for invasive amebiasis, and other nitroimidazoles have greatly simplified the chemotherapy of this disease. However, eradication of E. histolytica infection after completion of MTZ therapy requires additional treatment with luminal amebicides, such as paramomycin. After decades of the introduction of MTZ and other nitroimidazoles in the therapy of amebiasis, there have been few innovations in treating amebic infections. Meanwhile, amebiasis remains among the leading causes of morbidity and mortality in the contemporary world. The toxic effects of MTZ and recent failures in the treatment of several intestinal protozoan parasites, has led to a search for other amebicidal drugs. A recent advance is the demonstration of the effect of nitazoxanide, which has broad spectrum of antiparasitic activity, against E. histolytica. This compound could be the key in the therapy of amebiasis by its action against both luminal and invasive parasite forms. However, the design of an effective vaccine against the infection is still being desirable. Work is underway to develop a vaccine and recent experimental studies are promising. The aim of this review is to examine and discuss the most important aspects of current antiamebic pharmacotherapy and the prospects for development of new drugs and a vaccine.
Asunto(s)
Humanos , Amebiasis/tratamiento farmacológico , Amebicidas/uso terapéutico , Vacunas , Diseño de FármacosRESUMEN
Over a two year period, the incidence of hepatitis C virus (HCV) infection was evaluated in 29 hemodialysis patients, aged between 15 and 75 years (mean ± SD: 45 ± 39.5 years), from the University Hospital Hemodyalisis Unit, Maracaibo, Zulia State, Venezuela. Anti-HCV antibodies were determined using a fourth generation ELISA (Innotest HCV Ab IV) kit and positive blood samples were tested using a recombinant assay kit (Inno-LIA HCV Ab III), both kits from Innogenetics N.V., Belgium. The findings indicate a lack of HCV seroconversion in the hemodialysis patients over the study period, confirmed by the recombinant assay. Risk factors for HCV infection were 0.3270 (95% confidence interval: 0.01323-8.080) in patients undergoing hemodialysis. The findings suggest a lack of significant sources for HCV infection due to the preventive measures to avoid its transmission in the hemodialysis unit.
Asunto(s)
Hepacivirus/aislamiento & purificación , Anticuerpos contra la Hepatitis C/sangre , Hepatitis C/epidemiología , Diálisis Renal , Adolescente , Adulto , Anciano , Ensayo de Inmunoadsorción Enzimática , Hepacivirus/inmunología , Hepatitis C/prevención & control , Humanos , Immunoblotting , Incidencia , Persona de Mediana Edad , Factores de Riesgo , Venezuela/epidemiologíaRESUMEN
Over a two year period, the incidence of hepatitis C virus (HCV) infection was evaluated in 29 hemodialysis patients, aged between 15 and 75 years (mean ± SD: 45 ± 39.5 years), from the University Hospital Hemodyalisis Unit, Maracaibo, Zulia State, Venezuela. Anti-HCV antibodies were determined using a fourth generation ELISA (Innotest HCV Ab IV) kit and positive blood samples were tested using a recombinant assay kit (Inno-LIA HCV Ab III), both kits from Innogenetics N.V., Belgium. The findings indicate a lack of HCV seroconversion in the hemodialysis patients over the study period, confirmed by the recombinant assay. Risk factors for HCV infection were 0.3270 (95 percent confidence interval: 0.01323-8.080) in patients undergoing hemodialysis. The findings suggest a lack of significant sources for HCV infection due to the preventive measures to avoid its transmission in the hemodialysis unit.
Durante período de 2 anos, estudamos a incidência da infecção pelo vírus da hepatite C (VHC) em 29 pacientes em tratamento de diálise, com idades entre 15 e 75 anos (c ± DS; 45 ± 39,5 anos), procedentes da unidade de hemodiálise do Hospital Universitário de Maracaibo, Estado Zulia, Venezuela. Para a detecção dos anticorpos contra o VHC (anti-VHC) utilizamos a técnica de imunoensaio enzimático (ELISA, Innotest HCV Ab IV) e em amostras reativas por ELISA, utilizamos o método de immunoblot recombinante de terceira geração (Inno-LIA HCV Ab III), ambos da casa comercial Innogenetics N.V., Bélgica. Os resultados demonstram ausência de soroconversão ao VHC nos pacientes hemodializados durante o período estudado, o que foi confirmado pelo método de imunoblot recombinante. Os fatores de risco ao VHC foram 0,327 (95 por cento CI: 0,01323 - 8,080) nos pacientes submetidos ao tratamento de diálise. Nossos resultados sugerem ausência de fontes de infecção neste centro de hemodiálise e que as medidas universais de controle de infecção são cumpridas.